Phospho-CAMK2A (Thr286) Antibody

What is the significance of Thr286 phosphorylation in CaMKII function?

Thr286 phosphorylation represents a critical regulatory mechanism for CaMKII activity. When Ca²⁺/calmodulin binds to the CaMKII regulatory domain, it relieves autoinhibition and activates the kinase. The activated CaMKII then autophosphorylates at Thr286, which renders the kinase constitutively active even after Ca²⁺/calmodulin dissociates . This autophosphorylation serves as a molecular memory mechanism that extends the activation of CaMKII beyond the initial calcium signal. Phosphorylation at Thr286 is regulated through a balance with protein phosphatase 1 (PP1), which dephosphorylates phospho-CaMKII at Thr286, while protein kinase A (PKA) prevents this dephosphorylation through an inhibitory effect on PP1 .

Which experimental applications are validated for Phospho-CaMKII (Thr286) antibodies?

Phospho-CaMKII (Thr286) antibodies have been validated for multiple experimental applications in research settings. These include Western blotting (with recommended dilutions of 1:1000) , enzyme immunoassays (EIA), ELISA, flow cytometry, and immunocytochemistry techniques . For immunofluorescence applications, researchers have successfully used these antibodies to detect phosphorylated CaMKII in fixed cells by permeabilizing with 0.1% Triton X-100 and blocking with 3% BSA-PBS before overnight incubation with the antibody . These diverse applications make Phospho-CaMKII (Thr286) antibodies versatile tools for studying CaMKII activation across multiple experimental platforms.

How can I verify the specificity of a Phospho-CaMKII (Thr286) antibody?

Verifying antibody specificity is crucial for experimental validity. A recommended approach is to perform parallel analyses with positive and negative controls. One effective method involves treating samples with lambda phosphatase (λ-PPase), which removes phosphate groups, as a negative control. In immunofluorescence experiments, cells treated with λ-PPase show significantly reduced or absent staining compared to untreated cells when probed with Phospho-CaMKII (Thr286) antibodies . Additionally, specificity can be confirmed using samples expressing CaMKII with point mutations at the Thr286 site (e.g., T286A), which should not be recognized by the phospho-specific antibody . Cross-reactivity testing with other phosphorylation sites should also be performed to ensure the antibody doesn't recognize other phosphorylated residues like Thr305/306 .

What are the species cross-reactivity profiles for Phospho-CaMKII (Thr286) antibodies?

Most commercially available Phospho-CaMKII (Thr286) antibodies demonstrate cross-reactivity across multiple mammalian species. According to the product information, these antibodies typically react with human, mouse, and rat samples (H, M, R) . This cross-reactivity is due to the high conservation of the CaMKII sequence surrounding the Thr286 phosphorylation site across mammalian species. When planning experiments with tissues or cells from other species, researchers should verify reactivity or conduct preliminary tests to confirm antibody performance, as reactivity with non-mammalian species may vary and should not be assumed without validation.

How can single-molecule assays be used to quantify CaMKII Thr286 phosphorylation?

Single-molecule assays provide a powerful approach for quantifying Thr286 phosphorylation with high sensitivity. One sophisticated methodology involves fusing CaMKII to an N-terminal fluorescent protein (mEGFP) and a biotin tag, enabling capture and visualization of individual CaMKII holoenzymes on streptavidin-coated glass slides using total internal reflection fluorescence (TIRF) microscopy . After immobilization, holoenzymes can be exposed to various activation conditions and their phosphorylation status probed using phospho-specific antibodies against Thr286 and Thr305/306, labeled with different fluorophores (e.g., Alexa-594 for pThr286 and Alexa-647 for pThr305/306) .

This approach allows quantification of phosphorylation in two ways: first, by measuring the fraction of CaMKII holoenzymes showing detectable phosphorylation through co-localization of green (GFP) and red (pThr286) spots; second, by compiling intensity distributions for pThr286 signals to quantify the extent of activating phosphorylation per holoenzyme . The integrated intensity of the pThr286 signal, normalized by the total number of holoenzymes detected, reflects the mean level of phosphorylation per holoenzyme. This method has been successfully used to determine the EC₅₀ value for CaMKII-α activation by Ca²⁺/CaM, yielding values in the range of 50-100 nM, consistent with previously reported measurements .

What are the differential dephosphorylation kinetics between Thr286 and Thr305/306 sites?

Research has revealed striking differences in the dephosphorylation kinetics of the activating (Thr286) and inhibitory (Thr305/306) phosphorylation sites. Single-molecule studies demonstrate that phosphorylated Thr286 exhibits significant resistance to rapid dephosphorylation compared to phosphorylated Thr305/306 when exposed to phosphatases such as lambda phosphatase . This differential susceptibility suggests that pThr286 may be less accessible to phosphatases than pThr305/306, possibly due to structural constraints within the CaMKII holoenzyme.

Unexpectedly, the addition of Ca²⁺/CaM to phosphorylated CaMKII enhances the rate of dephosphorylation at Thr286 by approximately 4-fold for both CaMKII-α and CaMKII-β* isoforms . When Ca²⁺/CaM is present, the pThr286 signal diminishes at a rate comparable to the dephosphorylation rate of pThr305/306. This effect occurs independently of kinase activity, as it does not require the addition of ATP . These findings suggest a complex regulatory mechanism where Ca²⁺/CaM binding induces conformational changes that increase phosphatase accessibility to the Thr286 site, potentially serving as a reset mechanism for CaMKII activity.

How do different CaMKII isoforms vary in their Thr286 phosphorylation dynamics?

Different CaMKII isoforms exhibit distinct phosphorylation dynamics at Thr286, likely due to variations in their structural features, particularly the length and flexibility of linker regions. While most studies have focused primarily on CaMKII-α, research indicates that the balance of phosphorylation between activating (Thr286) and inhibitory (Thr305/306) sites varies across isoforms . These differences affect how each isoform responds to Ca²⁺/CaM stimulation and subsequent activation.

The variable domain connecting the kinase domain to the association domain plays a crucial role in determining these phosphorylation dynamics. Isoforms with longer linkers may exhibit different spatial arrangements of kinase domains within the holoenzyme, affecting the accessibility of phosphorylation sites and the ability of kinase domains to engage in trans-autophosphorylation events . These isoform-specific differences in phosphorylation dynamics may contribute to specialized functions of CaMKII in different cellular contexts and tissues, though the exact mechanisms require further investigation to fully elucidate.

What is the relationship between Ca²⁺/CaM concentration and Thr286 phosphorylation levels?

Single-molecule studies reveal a direct relationship between Ca²⁺/CaM concentration and Thr286 phosphorylation levels. Increasing the concentration of Ca²⁺/CaM from 20 nM to 5 μM, while maintaining a constant saturating concentration of Ca²⁺ (100 μM), results in progressively higher levels of phosphorylation at Thr286 . The EC₅₀ value for CaMKII-α activation by Ca²⁺/CaM derived from these measurements falls in the range of 50-100 nM, consistent with previously reported values .

This dose-dependent relationship highlights the graded response of CaMKII to calcium signaling, where the extent of Thr286 phosphorylation—and consequently the degree of constitutive activation—depends on the concentration of Ca²⁺/CaM. This property allows CaMKII to function as a molecular integrator of calcium signals, with different intensities and durations of calcium influx producing different levels of persistent activation through Thr286 phosphorylation. Understanding this relationship is crucial for interpreting CaMKII activation in physiological contexts with varying calcium dynamics.

What are the optimal immunofluorescence protocols for Phospho-CaMKII (Thr286) antibodies?

Successful immunofluorescence detection of phosphorylated CaMKII requires careful attention to fixation, permeabilization, and blocking conditions. An optimized protocol based on validated research involves the following steps: First, cells should be fixed with formalin to preserve phosphorylation status. After fixation, permeabilize cells with 0.1% Triton X-100 in TBS for 5-10 minutes at room temperature to allow antibody access to intracellular targets . Block non-specific binding sites with 3% BSA-PBS for 30 minutes at room temperature before incubating with the Phospho-CaMKII (Thr286) antibody at an appropriate dilution (typically 1:50) overnight in a humidified chamber .

After primary antibody incubation, wash cells thoroughly with PBST and then incubate with a fluorophore-conjugated secondary antibody (matching the species of the primary antibody) for 45 minutes at room temperature in the dark . For co-localization studies, F-actin can be stained with fluorescent phalloidin and nuclei with DAPI. The primary antibody incubation time should be optimized to ensure near-saturation of phospho-sites; approximately 45 minutes has been determined to be optimal in many experimental settings . This protocol typically yields clear visualization of phosphorylated CaMKII with minimal background when imaged using confocal or epifluorescence microscopy.

How can I quantitatively assess phosphorylation levels in Western blot applications?

Quantitative assessment of Thr286 phosphorylation by Western blotting requires careful normalization and controls. Begin with standard Western blotting procedures using a 1:1000 dilution of the Phospho-CaMKII (Thr286) antibody . For quantitative analysis, include both phosphorylated and total CaMKII measurements from the same samples, preferably on the same membrane if using fluorescent secondary antibodies with different emission wavelengths, or on stripped and reprobed membranes if using chemiluminescence.

Normalization should proceed in two steps: first, normalize the phospho-CaMKII signal to the corresponding total CaMKII signal in each sample to account for variations in protein loading and expression levels. Second, compare these normalized values across experimental conditions relative to an appropriate control (e.g., unstimulated or baseline condition). Include positive controls (maximally stimulated samples) and negative controls (samples treated with lambda phosphatase) to define the dynamic range of your assay. For statistical validity, perform at least three independent experiments and analyze the results using appropriate statistical tests.

What approaches can distinguish between different CaMKII isoforms in phosphorylation studies?

Distinguishing between phosphorylated CaMKII isoforms requires specialized approaches due to their structural similarities. One effective strategy employs isoform-specific antibodies in combination with phospho-specific antibodies. While the Phospho-CaMKII (Thr286) antibody recognizes the phosphorylated form of multiple CaMKII isoforms, subsequent probing with isoform-specific antibodies can identify which particular isoform is phosphorylated .

For more precise discrimination, researchers can use genetic approaches by expressing tagged versions of specific CaMKII isoforms (with mEGFP or other tags) in cellular systems, followed by immunoprecipitation and phosphorylation analysis . Single-molecule assays provide another powerful approach, allowing direct comparison of phosphorylation dynamics between different isoforms under identical conditions. For instance, studies have revealed differences in phosphorylation patterns between CaMKII-α and CaMKII-β isoforms, with variations in their susceptibility to phosphatases and responses to Ca²⁺/CaM . Mass spectrometry-based approaches can also identify phosphorylated peptides specific to each isoform, offering a comprehensive analysis of isoform-specific phosphorylation states in complex samples.

How should phosphatase treatments be optimized when validating antibody specificity?

Phosphatase treatments serve as crucial negative controls for validating the specificity of Phospho-CaMKII (Thr286) antibodies. Optimization requires careful consideration of several parameters. For lambda phosphatase (λ-phosphatase) treatments, researchers should determine the optimal enzyme concentration through titration experiments. Studies have shown that 400 units of λ-phosphatase represent a saturating amount, with no further reduction in phosphorylation observed at higher concentrations .

The reaction conditions must be carefully controlled, with the inclusion of 1 mM MnCl₂ as a cofactor for optimal λ-phosphatase activity . Incubation time is another critical parameter, with 45 minutes typically sufficient for complete dephosphorylation under optimal conditions . When performing these validations in cellular contexts, it's important to first inhibit endogenous kinase activity using inhibitors such as staurosporine (100 μM) to prevent re-phosphorylation during the phosphatase treatment .

For analyzing phosphatase-treated samples, researchers should compare phospho-specific antibody signals between treated and untreated samples using both qualitative (imaging) and quantitative (signal intensity measurements) approaches. A valid phospho-specific antibody should show significantly reduced or absent signal in phosphatase-treated samples compared to untreated controls, confirming its specificity for the phosphorylated epitope.

What factors contribute to inconsistent phospho-CaMKII (Thr286) antibody results?

Several factors can contribute to inconsistent results when using phospho-CaMKII (Thr286) antibodies. Sample preparation methods significantly impact phosphorylation preservation; delays between cell/tissue collection and fixation/lysis can lead to dephosphorylation by endogenous phosphatases. Researchers should use phosphatase inhibitors in all buffers and maintain samples at cold temperatures to minimize dephosphorylation .

The timing of fixation is also critical, as phosphorylation is a dynamic process that changes rapidly in response to stimuli. Antibody storage conditions affect performance; repeated freeze-thaw cycles can degrade antibody quality, leading to reduced sensitivity and specificity. Additionally, lot-to-lot variations in antibody production can introduce inconsistencies, even when using the same catalog number .

Background signals may result from non-specific binding, particularly in tissues with high endogenous phosphatase activity or autofluorescence. These issues can be mitigated by optimizing blocking conditions (using 5% BSA rather than milk, which contains active phosphatases) and implementing more stringent washing procedures . Cross-reactivity with other phosphorylated epitopes should be evaluated, especially in experiments examining multiple phosphorylation sites simultaneously.

What are the limitations of quantifying absolute phosphorylation levels with antibody-based methods?

While antibody-based methods are valuable for detecting phosphorylation, they have inherent limitations for absolute quantification. In single-molecule assays, integrated intensity values cannot definitively determine the absolute number of phosphate groups within each holoenzyme because complete detection of every phosphate group cannot be guaranteed . Steric interference between antibodies or with the glass support may prevent complete labeling, resulting in an underestimation of phosphorylation levels.

These limitations necessitate using antibody fluorescence intensities as relative rather than absolute measures of phosphorylation extent . To address these constraints, researchers should include appropriate controls and standards in each experiment to enable relative comparisons across conditions. Complementary approaches such as mass spectrometry or radioactive labeling techniques can provide more accurate absolute quantification of phosphorylation stoichiometry.

For Western blotting applications, the relationship between signal intensity and phosphorylation level may not be strictly linear across the entire dynamic range, particularly at very high or low phosphorylation levels. Therefore, researchers should validate the linear range of detection for their specific experimental setup and include calibration standards when absolute quantification is required.

How are Phospho-CaMKII (Thr286) antibodies being applied in neuroscience research?

Phospho-CaMKII (Thr286) antibodies have become essential tools in neuroscience research, particularly for investigating synaptic plasticity mechanisms underlying learning and memory. These antibodies enable researchers to visualize the spatial and temporal dynamics of CaMKII activation in neurons following different stimulation protocols. By combining these antibodies with electrophysiological recordings and behavioral assays, researchers can correlate CaMKII activation patterns with functional outcomes at cellular and organismal levels.

Recent applications include mapping activity-dependent CaMKII phosphorylation across brain regions during memory formation and recall, investigating alterations in CaMKII signaling in neurological disorders, and examining the subcellular localization of activated CaMKII within dendritic spines during synaptic potentiation. The development of single-molecule assays using these antibodies has further refined our understanding of how CaMKII functions as a molecular switch in neurons, converting transient calcium signals into persistent biochemical changes . These sophisticated applications continue to enhance our understanding of the molecular mechanisms underlying neural function in both health and disease states.

What role does monitoring Thr286 phosphorylation play in developing therapies targeting CaMKII dysregulation?

Monitoring Thr286 phosphorylation provides critical insights for therapeutic development targeting CaMKII dysregulation in various pathological conditions. Abnormal CaMKII activity has been implicated in numerous disorders, including cardiac arrhythmias, neurodegenerative diseases, and certain cancers. Phospho-CaMKII (Thr286) antibodies enable researchers to assess the efficacy of potential therapeutic compounds in normalizing CaMKII activity in disease models.

In drug discovery pipelines, these antibodies facilitate high-throughput screening of compounds that modulate CaMKII phosphorylation state, either directly or through upstream regulators. The differential dephosphorylation kinetics between Thr286 and Thr305/306 sites, revealed through antibody-based studies, highlight the potential for developing site-specific interventions that selectively target particular aspects of CaMKII regulation . Understanding how Ca²⁺/CaM binding affects Thr286 dephosphorylation rates also suggests novel therapeutic strategies that might exploit this mechanism to reset pathologically elevated CaMKII activity .

As personalized medicine advances, phospho-specific antibodies may help identify patient subgroups with distinct CaMKII phosphorylation profiles, potentially guiding treatment selection and monitoring therapeutic responses in diseases characterized by CaMKII dysregulation.